Balance Sheet

Cash Flow Statement

Daily Values

Growth Metrics

Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Capital Expenditures (QoQ)Capital Expenditures Growth (1y)Capital Expenditures Growth (3y)Capital Expenditures Growth (5y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Investing Activities Growth (5y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)Cash from Operations Growth (5y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Growth (5y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBIT Margin Growth (5y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBITDA Margin Growth (5y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Growth (5y)EBT Margin (QoQ)EBT Margin Growth (1y)EBT Margin Growth (3y)EBT Margin Growth (5y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Basic) Growth (5y)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin (QoQ)FCF Margin Growth (1y)FCF Margin Growth (3y)FCF Margin Growth (5y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Free Cash Flow Growth (5y)Gross Margin (QoQ)Gross Margin Growth (1y)Gross Margin Growth (3y)Gross Margin Growth (5y)Gross Profit (QoQ)Gross Profit Growth (1y)Gross Profit Growth (3y)Gross Profit Growth (5y)Interest Coverage Ratio (QoQ)Interest Coverage Ratio Growth (1y)Interest Coverage Ratio Growth (3y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Cash Flow Growth (5y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income Growth (5y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Income towards Common Stockholders Growth (5y)Net Margin (QoQ)Net Margin Growth (1y)Net Margin Growth (3y)Net Margin Growth (5y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Income Growth (5y)Operating Margin (QoQ)Operating Margin Growth (1y)Operating Margin Growth (3y)Operating Margin Growth (5y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Profit After Tax Growth (5y)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Return on Assets (QoQ)Return on Assets Growth (1y)Return on Assets Growth (3y)Return on Assets Growth (5y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Capital Employed Growth (5y)Return on Equity (QoQ)Return on Equity Growth (1y)Return on Equity Growth (3y)Return on Equity Growth (5y)Return on Sales (QoQ)Return on Sales Growth (1y)Return on Sales Growth (3y)Return on Sales Growth (5y)Revenue (QoQ)Revenue Growth (1y)Revenue Growth (3y)Revenue Growth (5y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Share-based Compensation Growth (3y)Share-based Compensation Growth (5y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)Tax Rate (QoQ)Total Debt (QoQ)Total Debt Growth (1y)Total Debt Growth (3y)Total Debt Growth (5y)

Others

Cellectis (CLLS) Profit After Tax Growth (1y) (2015 - 2026)

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	PAT Growth (1y) (Qtr)
1	Quantum Biopharma	1,216,509.61 Bn	1,216,509.61 Bn	-	65.80%
2	Alterity Therapeutics	764,224.41 Bn	764,224.38 Bn	-	-
3	Legend Biotech	2,716.00 Bn	2,715.71 Bn	242.10 Mn	17.05%
4	Nanobiotix	2,248.83 Bn	2,248.77 Bn	-	-
5	Akari Therapeutics	1,951.18 Bn	1,951.17 Bn	-	-290.15%
6	Vertex Pharmaceuticals	113.69 Bn	106.44 Bn	2.59 Bn	59.59%
7	Evaxion A	64.16 Bn	64.14 Bn	-	-129.68%
8	Regeneron Pharmaceuticals	63.94 Bn	55.18 Bn	3.31 Bn	-10.08%
9	Alnylam Pharmaceuticals	40.13 Bn	37.12 Bn	959.66 Mn	1,228.66%
10	Cellectis	20.83 Bn	20.62 Bn	-	2.00%

Historic Data

Download Data 🔒

Date	Value
Mar 31, 2026	2.00%
Dec 31, 2025	-544.41%
Sep 30, 2025	-79.02%
Jun 30, 2025	-20.94%
Mar 31, 2025	-421.25%
Dec 31, 2024	111.80%
Sep 30, 2024	-31.88%
Jun 30, 2024	-17.94%
Mar 31, 2024	118.76%
Dec 31, 2023	-75.73%
Sep 30, 2023	44.08%
Jun 30, 2023	67.28%
Mar 31, 2023	5.76%
Dec 31, 2022	-1.71%
Sep 30, 2022	64.95%
Jun 30, 2022	1.79%
Mar 31, 2022	-107.94%
Dec 31, 2021	-160.09%
Sep 30, 2021	-165.46%
Jun 30, 2021	-323.75%
Mar 31, 2021	-192.43%
Dec 31, 2020	213.54%
Sep 30, 2020	-72.46%
Jun 30, 2020	66.64%
Mar 31, 2020	208.88%
Dec 31, 2019	-57.91%
Sep 30, 2019	23.03%
Jun 30, 2019	-276.23%
Mar 31, 2019	43.61%
Dec 31, 2018	9.25%
Sep 30, 2018	64.97%
Jun 30, 2018	63.26%
Mar 31, 2018	-36.77%
Dec 31, 2017	-113.52%
Sep 30, 2017	-414.13%
Jun 30, 2017	-274.99%
Mar 31, 2017	39.17%
Dec 31, 2016	-248.89%
Sep 30, 2016	1.01%
Jun 30, 2016	71.15%
Mar 31, 2016	-555.42%
Dec 31, 2015	36,041.61%